28-Feb-2025
Stereotaxis Q4 2024 Earnings Preview
Seeking Alpha News (Fri, 28-Feb 12:51 PM ET)
Stereotaxis to Present at 45th Annual TD Cowen Healthcare Conference
Globe Newswire (Tue, 25-Feb 8:03 AM ET)
Stereotaxis to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025
Globe Newswire (Mon, 3-Feb 4:05 PM ET)
Stereotaxis Announces First GenesisX Robotic System Order
Globe Newswire (Thu, 30-Jan 8:09 AM ET)
Stereotaxis Receives CE Mark Approval for the MAGiC Ablation Catheter
Globe Newswire (Mon, 27-Jan 8:00 AM ET)
Globe Newswire (Tue, 14-Jan 7:21 AM ET)
Magbot Robotic Magnetic Navigation Ablation Catheter Approved by China's NMPA
Globe Newswire (Mon, 9-Dec 7:25 AM ET)
Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems; Disposables, Royalty; and Sublease, of which a majority of revenue is generated from the Disposables, service and accessories stream. The company generates the majority of revenue from the United States.
Stereotaxis trades on the AMEX stock market under the symbol STXS.
As of February 28, 2025, STXS stock price declined to $2.06 with 1,168,665 million shares trading.
STXS has a market cap of $174.39 million. This is considered a Micro Cap stock.
Last quarter Stereotaxis reported $9 million in Revenue and -$.08 earnings per share. This beat revenue expectation by $2 million and missed earnings estimates by -$.03.
In the last 3 years, STXS traded as high as $4.89 and as low as $1.33.
The top ETF exchange traded funds that STXS belongs to (by Net Assets): VTI, VXF, IWM, IWO, VTWO.
STXS has underperformed the market in the last year with a price return of -26.7% while the SPY ETF gained +18.8%. STXS has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -7.6% and -8.8%, respectively, while the SPY returned -0.4% and -2.5%, respectively.
STXS support price is $2.07 and resistance is $2.27 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that STXS shares will trade within this expected range on the day.